RELMADA THERAPEUTICS, INC. Cash and Cash Equivalents, Period Increase (Decrease)
RELMADA THERAPEUTICS, INC. (RLMD) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$24.05 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-15.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2020-05-15
- RELMADA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2020-03-31 was -$24.05M.
- RELMADA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-12-31 was $28.43M, a 1746.91% increase year-over-year.
- RELMADA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-09-30 was -$1.37M.
- RELMADA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-06-30 was $7.16M.
- RELMADA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2019 was $6.98M, a 1220.44% increase from fiscal 2018.
- RELMADA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2018 was $528.43K.
- RELMADA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$6.79M.
- RELMADA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$13.97M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2020-03-31 | -$24.05M 10-Q · filed 2020-05-15 | $4.38M derived: sum of 2 quarters · filed 2020-05-15 | $3.01M derived: sum of 3 quarters · filed 2020-05-15 | $10.17M derived: sum of 4 quarters · filed 2020-05-15 |
| 2019-12-31 | $28.43M derived: 10-KT 6 month − 10-Q 3 month · filed 2020-03-26 | $27.06M 10-KT · filed 2020-03-26 | $34.22M derived: sum of 3 quarters · filed 2020-03-26 | $33.85M derived: sum of 4 quarters · filed 2020-05-15 |
| 2019-09-30 | -$1.37M 10-Q · filed 2019-11-13 | $5.80M derived: sum of 2 quarters · filed 2020-03-26 | $5.42M derived: sum of 3 quarters · filed 2020-05-15 | $6.96M derived: sum of 4 quarters · filed 2020-05-15 |
| 2019-06-30 | $7.16M derived: 10-KT 12 month − 10-Q 9 month · filed 2020-03-26 | $6.79M derived: sum of 2 quarters · filed 2020-05-15 | $8.33M derived: sum of 3 quarters · filed 2020-05-15 | $6.98M 10-KT · filed 2020-03-26 |
| 2019-03-31 | -$372.90K 10-Q · filed 2020-05-15 | $1.17M derived: sum of 2 quarters · filed 2020-05-15 | -$185.09K 10-Q · filed 2019-05-15 | -$2.20M derived: sum of 4 quarters · filed 2020-05-15 |
| 2018-12-31 | $1.54M derived: 10-KT 6 month − 10-Q 3 month · filed 2020-03-26 | $187.81K 10-KT · filed 2020-03-26 | -$1.83M derived: sum of 3 quarters · filed 2020-03-26 | -$3.51M derived: sum of 4 quarters · filed 2020-03-26 |
| 2018-09-30 | -$1.35M 10-Q · filed 2019-11-13 | -$3.37M derived: sum of 2 quarters · filed 2020-03-26 | -$5.05M derived: sum of 3 quarters · filed 2020-03-26 | -$3.80M derived: sum of 4 quarters · filed 2020-03-26 |
| 2018-06-30 | -$2.02M derived: 10-KT 12 month − 10-Q 9 month · filed 2020-03-26 | -$3.70M derived: sum of 2 quarters · filed 2020-03-26 | -$2.45M derived: sum of 3 quarters · filed 2020-03-26 | $528.43K 10-KT · filed 2020-03-26 |
| 2018-03-31 | -$1.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-15 | -$426.94K derived: sum of 2 quarters · filed 2019-05-15 | $2.55M 10-Q · filed 2019-05-15 | $1.50M derived: sum of 4 quarters · filed 2019-05-15 |
| 2017-12-31 | $1.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-02-13 | $4.23M 10-Q · filed 2019-02-13 | $3.18M derived: sum of 3 quarters · filed 2019-02-13 | $1.23M derived: sum of 4 quarters · filed 2019-02-13 |
| 2017-09-30 | $2.97M 10-Q · filed 2018-11-13 | $1.93M derived: sum of 2 quarters · filed 2018-11-13 | -$29.73K derived: sum of 3 quarters · filed 2018-11-13 | -$1.54M derived: sum of 4 quarters · filed 2018-11-13 |
| 2017-06-30 | -$1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2018-09-28 | -$3.00M derived: sum of 2 quarters · filed 2018-09-28 | -$4.51M derived: sum of 3 quarters · filed 2018-09-28 | -$6.79M 10-K · filed 2018-09-28 |
| 2017-03-31 | -$1.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-05-14 | -$3.47M derived: sum of 2 quarters · filed 2018-05-14 | -$5.74M 10-Q · filed 2018-05-14 | -$8.59M derived: sum of 4 quarters · filed 2018-05-14 |
| 2016-12-31 | -$1.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-12 | -$3.79M 10-Q · filed 2018-02-12 | -$6.63M derived: sum of 3 quarters · filed 2018-02-12 | -$10.41M derived: sum of 4 quarters · filed 2018-02-12 |
| 2016-09-30 | -$2.28M 10-Q · filed 2017-11-14 | -$5.13M derived: sum of 2 quarters · filed 2017-11-14 | -$8.91M derived: sum of 3 quarters · filed 2017-11-14 | -$12.94M derived: sum of 4 quarters · filed 2017-11-14 |
| 2016-06-30 | -$2.85M derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-28 | -$6.63M derived: sum of 2 quarters · filed 2017-09-28 | -$10.67M derived: sum of 3 quarters · filed 2017-09-28 | -$13.97M 10-K · filed 2017-09-28 |
| 2016-03-31 | -$3.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-15 | -$7.82M derived: sum of 2 quarters · filed 2017-05-15 | -$11.12M 10-Q · filed 2017-05-15 | |
| 2015-12-31 | -$4.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-10 | -$7.34M 10-Q · filed 2017-02-10 | ||
| 2015-09-30 | -$3.30M 10-Q · filed 2016-11-10 | |||
| 2015-06-30 | -$3.09M 10-K · filed 2016-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |